Symbols / AVTX Stock $22.87 +4.86% Avalo Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
AVTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Garry A. Neil M.D.
Exch · Country NCM · United States
Market Cap 610.96M
Enterprise Value 399.11M
Income -78.26M
Sales 59.00K
FCF (ttm) -17.26M
Book/sh 4.49
Cash/sh 4.32
Employees 33
Insider 10d —
IPO Oct 14, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.63
PEG —
P/S 10,355.20
P/B 5.10
P/C —
EV/EBITDA -5.50
EV/Sales 6,764.53
Quick Ratio 7.60
Current Ratio 8.14
Debt/Eq 0.51
LT Debt/Eq —
EPS (ttm) -5.84
EPS next Y -3.45
EPS Growth —
Revenue Growth -69.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-23
Earnings (prior) 2026-03-23
ROA -34.12%
ROE -72.44%
ROIC —
Gross Margin 0.00%
Oper. Margin -334.61%
Profit Margin 0.00%
Shs Outstand 26.71M
Shs Float 20.16M
Insider Own 2.51%
Instit Own 92.91%
Short Float 23.07%
Short Ratio 5.93
Short Interest 5.24M
52W High 24.27
vs 52W High -5.77%
52W Low 3.39
vs 52W Low 574.63%
Beta 0.79
Impl. Vol. 1.05%
Rel Volume 4.58
Avg Volume 1.13M
Volume 5.20M
Target (mean) $40.09
Tgt Median $40.00
Tgt Low $24.00
Tgt High $52.00
# Analysts 11
Recom Strong_buy
Prev Close $21.81
Price $22.87
Change 4.86%
About

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$40.09
Mean price target
2. Current target
$22.87
Latest analyst target
3. DCF / Fair value
$-11.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$22.87
Low
$24.00
High
$52.00
Mean
$40.09

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-06 main Citizens Market Outperform → Market Outperform $62
2026-05-06 main Wedbush Outperform → Outperform $40
2026-05-06 main BTIG Buy → Buy $58
2026-04-13 reit BTIG Buy → Buy $40
2026-04-09 init Wolfe Research — → Outperform $48
2026-04-06 init Citizens — → Market Outperform $52
2026-03-25 main HC Wainwright & Co. Buy → Buy $40
2026-03-24 reit BTIG Buy → Buy $40
2026-02-02 init Guggenheim — → Buy $50
2026-01-15 reit HC Wainwright & Co. Buy → Buy $25
2025-12-18 init Mizuho — → Outperform $39
2025-09-29 reit BTIG Buy → Buy $40
2025-09-17 main HC Wainwright & Co. Buy → Buy $25
2025-08-15 init Cantor Fitzgerald — → Overweight —
2025-03-25 init Jefferies — → Buy $23
2025-03-25 init Stifel — → Buy $36
2025-03-20 reit HC Wainwright & Co. Neutral → Neutral —
2025-02-28 init Piper Sandler — → Overweight $48
2024-12-19 init BTIG — → Buy $40
2024-12-17 init LUCID CAPITAL MARKETS — → Buy $24
News
RSS: Latest AVTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-30 SULLIVAN CHRISTOPHER RYAN Chief Financial Officer — 16,915 $13.09 $222,589
2026-04-06 DOYLE MITTIE Officer — 3,970 $18.01 $71,508
2026-04-06 DOYLE MITTIE Officer — 3,970 $12.65 $50,220
2026-04-02 SULLIVAN CHRISTOPHER RYAN Chief Financial Officer — 15,959 $15.86 $270,593
2026-04-01 DOYLE MITTIE Officer — 679 $16.00 $10,864
2026-04-01 DOYLE MITTIE Officer — 679 $8.04 $5,459
2026-03-27 KAPLAN GILLA Director — 3,166 — —
2026-03-27 GOLDMAN JONATHAN Director — 3,166 — —
2026-03-27 NEIL GARRY A. M.D. Chief Executive Officer — 64,866 — —
2026-03-27 CHAN MITCHELL Director — 3,166 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.06
-86.62%
0.44
-77.08%
1.92
-89.34%
18.05
Operating Revenue
0.06
-86.62%
0.44
-77.08%
1.92
-89.34%
18.05
Cost Of Revenue
0.00
+100.00%
-0.37
-128.50%
1.28
-62.61%
3.43
Reconciled Cost Of Revenue
0.00
+100.00%
-0.37
-128.50%
1.28
-61.16%
3.31
Gross Profit
0.06
-92.69%
0.81
+26.09%
0.64
-95.62%
14.62
Operating Expense
72.98
+75.11%
41.68
+73.05%
24.08
-53.74%
52.06
Research And Development
50.08
+104.95%
24.44
+77.29%
13.78
-55.97%
31.31
Selling General And Administration
22.90
+32.82%
17.24
+67.39%
10.30
-50.27%
20.71
Selling And Marketing Expense
0.47
-40.43%
0.79
+2290.91%
0.03
-56.58%
0.08
General And Administrative Expense
22.43
+36.34%
16.45
+60.24%
10.27
-50.24%
20.64
Salaries And Wages
14.19
+75.49%
8.08
+79.76%
4.50
-63.90%
12.46
Other Gand A
8.24
-1.49%
8.37
+45.03%
5.77
-29.44%
8.18
Total Expenses
72.98
+76.67%
41.31
+62.85%
25.37
-54.28%
55.49
Operating Income
-72.92
-78.43%
-40.87
-74.33%
-23.44
+37.38%
-37.44
Total Operating Income As Reported
-72.92
-6.44%
-68.51
-150.49%
-27.35
—
EBITDA
-72.58
-78.32%
-40.70
-74.79%
-23.29
+37.53%
-37.27
Normalized EBITDA
-63.06
-45.82%
-43.25
-131.77%
-18.66
+49.94%
-37.27
Reconciled Depreciation
0.34
+103.55%
0.17
+6.96%
0.16
-4.82%
0.17
EBIT
-72.92
-78.43%
-40.87
-74.33%
-23.44
+37.38%
-37.44
Total Unusual Items
-9.52
-474.21%
2.54
+154.98%
-4.63
0.00
Total Unusual Items Excluding Goodwill
-9.52
-474.21%
2.54
+154.98%
-4.63
0.00
Special Income Charges
0.00
+100.00%
-36.86
-843.46%
-3.91
0.00
Other Special Charges
—
27.64
—
—
Impairment Of Capital Assets
—
0.00
-100.00%
3.91
0.00
Restructuring And Mergern Acquisition
0.00
-100.00%
9.22
0.00
—
Net Income
-78.26
-122.78%
-35.13
-11.37%
-31.54
+24.28%
-41.66
Pretax Income
-78.09
-123.03%
-35.02
-11.05%
-31.53
+24.26%
-41.63
Net Non Operating Interest Income Expense
4.35
+31.37%
3.31
+196.93%
-3.42
+18.06%
-4.17
Interest Expense Non Operating
—
-3.32
-197.07%
3.42
-18.06%
4.17
Net Interest Income
4.35
+31.37%
3.31
+196.93%
-3.42
+18.06%
-4.17
Interest Expense
—
-3.32
-197.07%
3.42
-18.06%
4.17
Other Income Expense
-9.52
-474.21%
2.54
+154.49%
-4.67
-23245.00%
-0.02
Other Non Operating Income Expenses
—
-0.01
+88.10%
-0.04
-110.00%
-0.02
Gain On Sale Of Security
-9.52
-124.16%
39.41
+5572.92%
-0.72
—
Tax Provision
0.17
+44.74%
0.11
+714.29%
0.01
-50.00%
0.03
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-2.00
-474.21%
0.53
+154.98%
-0.97
0.00
Net Income Including Noncontrolling Interests
-78.26
-122.78%
-35.13
-11.37%
-31.54
+24.28%
-41.66
Net Income From Continuing Operation Net Minority Interest
-78.26
-122.78%
-35.13
-11.37%
-31.54
+24.28%
-41.66
Net Income From Continuing And Discontinued Operation
-78.26
-122.78%
-35.13
-11.37%
-31.54
+24.28%
-41.66
Net Income Continuous Operations
-78.26
-122.78%
-35.13
-11.37%
-31.54
+24.28%
-41.66
Net Income Discontinuous Operations
—
—
—
0.00
Normalized Income
-70.74
-90.47%
-37.14
-33.17%
-27.89
+33.05%
-41.66
Net Income Common Stockholders
-78.26
-122.78%
-35.13
-11.37%
-31.54
+24.28%
-41.66
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-20.91
+81.59%
-113.58
+89.32%
-1,063.20
Basic EPS
—
-7.94
+93.01%
-113.58
+89.32%
-1,063.20
Basic Average Shares
—
4.43
+1493.70%
0.28
+608.81%
0.04
Diluted Average Shares
—
7.50
+2599.19%
0.28
+608.81%
0.04
Diluted NI Availto Com Stockholders
-78.26
-122.78%
-35.13
-11.37%
-31.54
+24.28%
-41.66
Amortization
—
—
0.00
-100.00%
0.04
Amortization Of Intangibles Income Statement
—
—
0.00
-100.00%
0.04
Depreciation Amortization Depletion Income Statement
—
—
0.00
-100.00%
0.04
Depreciation And Amortization In Income Statement
—
—
0.00
-100.00%
0.04
Total Other Finance Cost
-4.35
-31.37%
-3.31
-196.93%
3.42
-18.06%
4.17
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
116.46
-22.74%
150.73
+618.01%
20.99
-37.08%
33.37
Current Assets
105.29
-24.19%
138.89
+1554.44%
8.39
-48.86%
16.42
Cash Cash Equivalents And Short Term Investments
98.34
-26.91%
134.55
+1714.51%
7.42
-43.71%
13.17
Cash And Cash Equivalents
15.86
-88.21%
134.55
+1714.51%
7.42
-43.71%
13.17
Other Short Term Investments
82.48
0.00
—
—
Receivables
—
0.61
+349.26%
0.14
-92.91%
1.92
Accounts Receivable
—
—
—
0.00
Other Receivables
—
0.61
+349.26%
0.14
-92.91%
1.92
Inventory
—
—
0.00
-100.00%
0.02
Prepaid Assets
—
—
—
—
Restricted Cash
0.04
+94.74%
0.02
+1800.00%
0.00
-93.33%
0.01
Other Current Assets
6.91
+59.84%
4.33
+413.05%
0.84
-34.65%
1.29
Total Non Current Assets
11.17
-5.66%
11.84
-6.00%
12.60
-25.68%
16.95
Net PPE
0.46
-61.95%
1.21
-38.47%
1.97
-18.50%
2.41
Gross PPE
0.71
-62.85%
1.92
-23.45%
2.51
-11.26%
2.83
Accumulated Depreciation
-0.25
+64.37%
-0.71
-31.00%
-0.54
-30.92%
-0.41
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.14
-51.06%
0.28
+0.00%
0.28
-16.07%
0.34
Other Properties
—
—
1.33
-24.06%
1.75
Leases
0.57
-64.87%
1.64
-26.43%
2.23
+201.08%
0.74
Goodwill And Other Intangible Assets
10.50
+0.00%
10.50
+0.00%
10.50
-27.11%
14.41
Goodwill
10.50
+0.00%
10.50
+0.00%
10.50
-27.11%
14.41
Other Intangible Assets
—
—
—
—
Other Non Current Assets
0.21
+60.31%
0.13
+0.00%
0.13
+0.00%
0.13
Total Liabilities Net Minority Interest
33.41
+88.75%
17.70
+29.30%
13.69
-69.09%
44.28
Current Liabilities
12.94
+85.92%
6.96
+50.71%
4.62
-79.12%
22.11
Payables And Accrued Expenses
8.42
+167.26%
3.15
-10.05%
3.50
-71.73%
12.38
Payables
0.46
-23.93%
0.61
+36.77%
0.45
-86.84%
3.39
Accounts Payable
0.14
-51.59%
0.28
-36.55%
0.45
-84.52%
2.88
Other Payable
0.33
+0.00%
0.33
—
0.51
Current Accrued Expenses
7.95
+213.19%
2.54
-16.89%
3.06
-66.04%
8.99
Pensionand Other Post Retirement Benefit Plans Current
4.13
+43.32%
2.88
+397.07%
0.58
-78.51%
2.70
Total Tax Payable
—
—
—
—
Income Tax Payable
—
—
—
—
Current Debt And Capital Lease Obligation
0.39
-30.99%
0.57
+5.77%
0.54
-91.69%
6.46
Current Debt
—
—
—
5.93
Other Current Borrowings
—
—
—
5.93
Current Capital Lease Obligation
0.39
-30.99%
0.57
+5.77%
0.54
+0.94%
0.53
Current Deferred Liabilities
—
—
0.00
-100.00%
0.09
Current Deferred Revenue
—
—
0.00
-100.00%
0.09
Other Current Liabilities
—
0.36
—
0.48
Total Non Current Liabilities Net Minority Interest
20.47
+90.59%
10.74
+18.40%
9.07
-59.08%
22.17
Long Term Debt And Capital Lease Obligation
—
—
—
13.49
Long Term Debt
—
—
—
13.49
Non Current Deferred Liabilities
0.43
+60.74%
0.27
+74.19%
0.15
+9.93%
0.14
Non Current Deferred Taxes Liabilities
0.43
+60.74%
0.27
+74.19%
0.15
+9.93%
0.14
Other Non Current Liabilities
2.04
-13.40%
2.35
-30.18%
3.37
-9.30%
3.71
Preferred Securities Outside Stock Equity
0.00
0.00
0.00
—
Stockholders Equity
83.05
-37.57%
133.03
+1721.36%
7.30
+166.92%
-10.91
Common Stock Equity
83.05
-37.57%
133.03
+1721.36%
7.30
+166.92%
-10.91
Capital Stock
0.02
+80.00%
0.01
+900.00%
0.00
0.00
Common Stock
0.02
+80.00%
0.01
+900.00%
0.00
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
18.51
+76.78%
10.47
+1206.14%
0.80
+1940.43%
0.04
Ordinary Shares Number
18.51
+76.78%
10.47
+1206.14%
0.80
+1940.43%
0.04
Additional Paid In Capital
531.49
+5.60%
503.29
+46.97%
342.44
+16.91%
292.91
Retained Earnings
-448.52
-21.14%
-370.26
-10.48%
-335.13
-10.31%
-303.82
Gains Losses Not Affecting Retained Earnings
0.07
0.00
—
—
Other Equity Adjustments
0.07
—
—
—
Total Equity Gross Minority Interest
83.05
-37.57%
133.03
+1721.36%
7.30
+166.92%
-10.91
Total Capitalization
83.05
-37.57%
133.03
+1721.36%
7.30
+184.09%
2.57
Working Capital
92.35
-30.00%
131.93
+3392.98%
3.78
+166.29%
-5.70
Invested Capital
83.05
-37.57%
133.03
+1721.36%
7.30
-14.08%
8.50
Total Debt
0.39
-30.99%
0.57
+5.77%
0.54
-97.31%
19.95
Net Debt
—
—
—
6.24
Capital Lease Obligations
0.39
-30.99%
0.57
+5.77%
0.54
+0.94%
0.53
Net Tangible Assets
72.55
-40.79%
122.53
+3931.46%
-3.20
+87.37%
-25.32
Tangible Book Value
72.55
-40.79%
122.53
+3931.46%
-3.20
+87.37%
-25.32
Derivative Product Liabilities
18.00
+121.67%
8.12
+46.31%
5.55
+14.91%
4.83
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-51.46
-4.90%
-49.06
-59.90%
-30.68
-14.69%
-26.75
Cash Flow From Continuing Operating Activities
-51.46
-4.90%
-49.06
-59.90%
-30.68
-14.69%
-26.75
Net Income From Continuing Operations
-78.26
-122.78%
-35.13
-11.37%
-31.54
+24.28%
-41.66
Depreciation Amortization Depletion
0.34
+103.55%
0.17
+6.96%
0.16
-4.82%
0.17
Depreciation And Amortization
0.34
+103.55%
0.17
+6.96%
0.16
-4.82%
0.17
Other Non Cash Items
-0.69
-102.87%
24.05
+1215.70%
1.83
+31.61%
1.39
Stock Based Compensation
13.62
+132.76%
5.85
+68.31%
3.48
-53.97%
7.55
Provisionand Write Offof Assets
—
—
—
1.00
Asset Impairment Charge
—
0.00
-100.00%
3.91
0.00
Deferred Tax
0.17
+44.74%
0.11
+714.29%
0.01
-50.00%
0.03
Deferred Income Tax
0.17
+44.74%
0.11
+714.29%
0.01
-50.00%
0.03
Operating Gains Losses
9.52
+124.16%
-39.41
-5572.92%
0.72
-87.65%
5.83
Gain Loss On Investment Securities
9.52
+124.16%
-39.41
-5572.92%
0.72
-85.09%
4.83
Change In Working Capital
3.84
+181.58%
-4.71
+49.05%
-9.24
-15300.00%
-0.06
Change In Receivables
0.00
+100.00%
-0.47
-126.64%
1.78
-38.09%
2.88
Changes In Account Receivables
—
—
0.00
-100.00%
1.06
Change In Inventory
—
0.00
-100.00%
0.02
+11.11%
0.02
Change In Prepaid Assets
-2.59
+9.86%
-2.87
-742.28%
0.45
-58.69%
1.08
Change In Payables And Accrued Expense
6.52
+611.46%
-1.27
+88.91%
-11.48
-178.81%
-4.12
Change In Accrued Expense
6.66
+699.64%
-1.11
+87.72%
-9.05
-149.12%
-3.63
Change In Payable
-0.15
+10.43%
-0.16
+93.31%
-2.44
-400.21%
-0.49
Change In Account Payable
-0.15
+10.43%
-0.16
+93.31%
-2.44
-400.21%
-0.49
Change In Other Working Capital
—
—
0.07
-20.45%
0.09
Change In Other Current Assets
—
—
—
0.00
Change In Other Current Liabilities
-0.09
+1.14%
-0.09
-15.79%
-0.08
-744.44%
-0.01
Investing Cash Flow
-81.72
-23055.06%
0.36
+367.67%
-0.13
-40.00%
-0.10
Cash Flow From Continuing Investing Activities
-81.72
-23055.06%
0.36
+367.67%
-0.13
-40.00%
-0.10
Net PPE Purchase And Sale
—
0.00
-100.00%
0.03
+126.32%
-0.10
Purchase Of PPE
—
—
0.00
+100.00%
-0.10
Sale Of PPE
—
0.00
-100.00%
0.03
0.00
Capital Expenditure
—
—
—
-0.10
Net Investment Purchase And Sale
-81.72
0.00
—
—
Purchase Of Investment
-113.72
0.00
—
—
Sale Of Investment
32.00
0.00
—
—
Net Business Purchase And Sale
0.00
-100.00%
0.36
0.00
—
Purchase Of Business
—
—
—
—
Net Other Investing Changes
—
—
-0.16
—
Financing Cash Flow
14.59
-91.70%
175.85
+602.22%
25.04
+270.37%
-14.70
Cash Flow From Continuing Financing Activities
14.59
-91.70%
175.85
+602.22%
25.04
+270.37%
-14.70
Net Issuance Payments Of Debt
—
0.00
+100.00%
-21.24
0.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
0.00
+100.00%
-21.24
0.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
0.00
+100.00%
-21.24
0.00
Net Long Term Debt Issuance
—
0.00
+100.00%
-21.24
0.00
Net Common Stock Issuance
14.76
-87.23%
115.62
+150.17%
46.22
+412.88%
-14.77
Common Stock Payments
—
—
—
-14.81
Repurchase Of Capital Stock
—
—
—
-14.81
Proceeds From Stock Option Exercised
0.80
-98.85%
69.44
+103546.27%
0.07
-8.22%
0.07
Net Other Financing Charges
-0.97
+89.46%
-9.22
—
—
Changes In Cash
-118.59
-193.27%
127.15
+2303.24%
-5.77
+86.11%
-41.55
Beginning Cash Position
134.70
+1684.76%
7.55
-43.33%
13.32
-75.72%
54.86
End Cash Position
16.11
-88.04%
134.70
+1684.76%
7.55
-43.33%
13.32
Free Cash Flow
-51.46
-4.90%
-49.06
-59.90%
-30.68
-14.28%
-26.85
Interest Paid Supplemental Data
—
0.00
-100.00%
1.93
-34.32%
2.93
Income Tax Paid Supplemental Data
—
—
—
0.00
Change In Income Tax Payable
—
—
—
0.00
Change In Tax Payable
—
—
—
0.00
Common Stock Issuance
14.76
-87.23%
115.62
+150.17%
46.22
+135838.24%
0.03
Earnings Losses From Equity Investments
—
—
—
—
Issuance Of Capital Stock
14.76
-87.23%
115.62
+150.17%
46.22
+135838.24%
0.03
Sale Of Business
0.00
-100.00%
0.36
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category